Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib Mesylate

16 Apr 2013

Abstract excerpt

Selective inhibition of BCR/ABL expression by RNA interference has been demonstrated as an effective strategy in CML treatment and a reversal to imatinib resistance. microRNAs (miRNAs) are small regulatory RNAs involved in post-transcriptional gene regulation. miR-203 is supposed to directly regulate ABL and BCR/ABL expression, however, the role of miR-203 in imatinib-resistant cells is not clear. Here, we report...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Mast cells and histamine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23613955
DOI: 10.1371/journal.pone.0061858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of BCR/ABL Protein Expression by miR-203 Sensitizes for Imatinib MesylatePMID 23613955Read ↗

miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 proteinSemantic proximity Read ↗

Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene ExpressionSemantic proximity Read ↗

Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene ExpressionSemantic proximity Read ↗

MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR–ABL proteinSemantic proximity Read ↗

Restoration of miR-424 suppresses BCR–ABL activity and sensitizes CML cells to imatinib treatmentSemantic proximity Read ↗

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.Semantic proximity Read ↗

SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinibSemantic proximity Read ↗

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)Semantic proximity Read ↗

Specific inhibition of bcr-abl gene expression by small interfering RNASemantic proximity Read ↗

The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.Semantic proximity Read ↗

Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patientsSemantic proximity Read ↗

Bim and Bad mediate imatinib-induced killing of Bcr/Abl <sup>+</sup> leukemic cells, and resistance due to their loss is overcome by a BH3 mimeticSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.